COMMUNIQUÉS West-GlobeNewswire
-
Axe Compute Appoints Two Technology and Telecom Luminaries to Board of Directors as Company Accelerates AI Infrastructure Strategy
17/03/2026 -
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
17/03/2026 -
ProPhase Labs Provides Business Update Highlighting Advancing Crown Medical Collections Activity
17/03/2026 -
Elicio Therapeutics Reports Inducement Grants
17/03/2026 -
PatchMD Named the World’s #1 Vitamin Patch Brand in 2026 — And It’s Not Even Close
17/03/2026 -
Former Peloton and Equinox Design Leader Cecilia Farooqi Joins Noom as Head of Product Design
17/03/2026 -
Longevity Health Holdings Closes Strategic Investment and Appoints Ram Ajjarapu as Chairman and CEO to Drive Acquisition-Focused Growth
17/03/2026 -
Bionano Announces Two-Fold Increase in OGM Studies Presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
17/03/2026 -
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
17/03/2026 -
ReFocus Eye Health Expands Presence Through Strategic Affiliation with Seven Partner Practices and Four Ambulatory Surgery Centers
17/03/2026 -
Elutia to Present at Sidoti’s Small-Cap Virtual Investor Conference March 18-19
17/03/2026 -
Achieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026
17/03/2026 -
PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application
17/03/2026 -
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026
17/03/2026 -
Quantum Cyber Aligns Strategy With Trump Administration's National Cyber Security Framework, Targets Acquisitions in Quantum and Cyber Defense Sectors
17/03/2026 -
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
17/03/2026 -
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
17/03/2026 -
Organoid COMMONS Announces Formation of Governing Board, Appointment of Alliance Director, and Announces Open Call for New COMMONS Members
17/03/2026 -
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic
17/03/2026
Pages